Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Hazardous drug

From Wikipedia, the free encyclopedia
(Redirected fromHazardous drugs)
Globe icon.
The examples and perspective in this articledeal primarily with the United States and do not represent aworldwide view of the subject. You mayimprove this article, discuss the issue on thetalk page, orcreate a new article, as appropriate.(November 2009) (Learn how and when to remove this message)

Inpharmacology,hazardous drugs are drugs that are known to cause harm, which may or may not includegenotoxicity (the ability to cause a change or mutation in genetic material). Genotoxicity might involvecarcinogenicity, the ability to causecancer in animal models, humans or both;teratogenicity, which is the ability to cause defects onfetal development or fetal malformation; and lastly hazardous drugs are known to have the potential to cause fertility impairment, which is a major concern for most clinicians.[1] These drugs can be classified asantineoplastics,cytotoxic agents,biological agents,antiviral agents andimmunosuppressive agents. This is why safe handling of hazardous drugs is crucial.

Safe handling

[edit]

Safe handling refers to the process in which health care workers adhere to practices set forth by national health and safety organizations, that have been designed to eliminate or significantly reduce occupational exposure. Some of these practices include but are not limited to, donning ofpersonal protective equipment such as a disposable gown, gloves, masks and the utilization of aclosed system drug transfer device. The key to safe handling is to protect the health care worker throughout the three phases of contact with the hazardous drugs. These phases are drug preparation, administration and disposal. Some studies have shown that while compounding hazardous drugs in a Class IIbiological safety cabinet (BSC) in conjunction with a closed-system drug transfer device, a significant decrease in drug contaminants inside a Class II BSC has resulted.[2] This led the Oncology Nursing Society (ONS) to make the statement in 2003 that a closed-system drug transfer device is viewed as one of safest measures to prevent hazardous drug exposure in a clinician's working environment.[3] However, aCochrane review published in 2018 that synthesized all available controlled studies found no evidence of a closed-system drug transfer device offering an additional decrease in contamination or exposure to safe handling practices alone.[4]

It has been determined that currentpersonal protective equipment (PPE) does not provide adequate protection against workers handling hazardous drugs—NIOSH states that "... measurable concentrations of some hazardous drugs have been documented in the urine of health care workers who prepared or administered them—even after safety precautions had been employed."[1] Further, NIOSH recommends that institutions should "consider using devices such as closed-system transfer devices. Closed systems limit the potential for generating aerosols and exposing workers".[1] Other guidelines outline that "As other products become available, they should meet the definition of aclosed system drug transfer device established by NIOSH and should be required to demonstrate their effectiveness in independent studies".[2]

See also

[edit]

References

[edit]
  1. ^abcNational Institute for Occupational Safety and Health (NIOSH). 2004. NIOSH Publication N. 2004-165https://www.cdc.gov/niosh/docs/2004-165/
  2. ^abAmerican Society of Health-System Pharmacists (ASHP). 2005. Retrieved June 19, 2006, fromhttp://www.ashp.org/
  3. ^Oncology Nursing Society (ONS). 2003. Safe handling of hazardous drugs.
  4. ^Gurusamy, Kurinchi Selvan; Best, Lawrence MJ; Tanguay, Cynthia; Lennan, Elaine; Korva, Mika; Bussières, Jean-François (2018-03-27)."Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff".Cochrane Database of Systematic Reviews.2019 (2) CD012860.doi:10.1002/14651858.cd012860.pub2.PMC 6360647.PMID 29582940.

External links

[edit]
SPs/MIs
(M phase)
Blockmicrotubule assembly
Block microtubule disassembly
DNA replication
inhibitor
DNA precursors/
antimetabolites
(S phase)
Folic acid
Purine
Pyrimidine
Deoxyribonucleotide
Topoisomerase inhibitors
(S phase)
I
II
II+Intercalation
Crosslinking of DNA
(CCNS)
Alkylating
Platinum-based
Nonclassical
Intercalation
Photosensitizers/PDT
Other
Enzyme inhibitors
Receptor antagonists
Other/ungrouped
Retrieved from "https://en.wikipedia.org/w/index.php?title=Hazardous_drug&oldid=1331299158"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2026 Movatter.jp